All In Biotech

Drug Trial Radar · NCT01562834

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Oct 21, 1998

Primary completion

Dec 1, 2002

Study completion Dec 1, 2002

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.

Conditions

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Interventions

  • somatropinDrug

    Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.

  • placeboDrug

    Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left ventricular mass measured with ultrasonography

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Angers, France

  • Novo Nordisk Investigational Site

    Boisguillaume, France

  • Novo Nordisk Investigational Site

    Brest, France

  • Novo Nordisk Investigational Site

    Caen, France

  • Novo Nordisk Investigational Site

    Grenoble, France

  • Novo Nordisk Investigational Site

    Le Kremlin-Bicêtre, France

  • Novo Nordisk Investigational Site

    Lille, France

  • Novo Nordisk Investigational Site

    Lorient, France

  • Novo Nordisk Investigational Site

    Lyon, France

  • Novo Nordisk Investigational Site

    Lyon, France

  • Novo Nordisk Investigational Site

    Marseille Cédex 05, France

  • Novo Nordisk Investigational Site

    Montpellier, France

  • Novo Nordisk Investigational Site

    Nantes, France

  • Novo Nordisk Investigational Site

    Nantes, France

  • Novo Nordisk Investigational Site

    Nice, France

  • Novo Nordisk Investigational Site

    Paris, France

  • Novo Nordisk Investigational Site

    Paris, France

  • Novo Nordisk Investigational Site

    Paris, France

  • Novo Nordisk Investigational Site

    Reims, France

  • Novo Nordisk Investigational Site

    Rennes, France

  • Novo Nordisk Investigational Site

    Strasbourg, France

  • Novo Nordisk Investigational Site

    Toulouse, France

  • Novo Nordisk Investigational Site

    Tours, France

  • Novo Nordisk Investigational Site

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.